Close Menu

NEW YORK – Paige said Wednesday it has closed a $45 million Series B financing round, bringing its total capital raised to more than $70 million.

Healthcare Venture Partners brought the largest contribution to a round in which Breyer Capital, Kenan Turnacioglu, and other funds contributed, Paige said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.